These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34347045)

  • 1. Organs-on-chip models for cardiovascular drug development.
    Zimmermann WH
    Cardiovasc Res; 2021 Nov; 117(12):e164-e165. PubMed ID: 34347045
    [No Abstract]   [Full Text] [Related]  

  • 2. The application of phenotypic high-throughput screening techniques to cardiovascular research.
    Etzion Y; Muslin AJ
    Trends Cardiovasc Med; 2009 Aug; 19(6):207-12. PubMed ID: 20211437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Future of Cardiovascular Therapeutics.
    MacRae CA; Roden DM; Loscalzo J
    Circulation; 2016 Jun; 133(25):2610-7. PubMed ID: 27324356
    [No Abstract]   [Full Text] [Related]  

  • 4. Biomimetic microsystems for cardiovascular studies.
    Inbody SC; Sinquefield BE; Lewis JP; Horton RE
    Am J Physiol Cell Physiol; 2021 May; 320(5):C850-C872. PubMed ID: 33760660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leptin and the cardiovascular system - a target for therapeutic interventions.
    Beltowski J
    Curr Pharm Des; 2014; 20(4):601-2. PubMed ID: 23688018
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapeutic potential of neuregulin-1 in cardiovascular disease.
    Mendes-Ferreira P; De Keulenaer GW; Leite-Moreira AF; Brás-Silva C
    Drug Discov Today; 2013 Sep; 18(17-18):836-42. PubMed ID: 23384772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of nitroxyl (HNO) in cardiovascular system: From biochemistry to pharmacology.
    Sun HJ; Wu ZY; Cao L; Zhu MY; Nie XW; Huang DJ; Sun MT; Bian JS
    Pharmacol Res; 2020 Sep; 159():104961. PubMed ID: 32474086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Beneficial Cardiovascular Effects of Natural Activators of Autophagy.
    Frati G; Vecchione C; Sciarretta S
    Circ Res; 2018 Sep; 123(8):947-949. PubMed ID: 30355035
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of geranylgeranylacetone upon cardiovascular diseases.
    Zeng S; Wang H; Chen Z; Cao Q; Hu L; Wu Y
    Cardiovasc Ther; 2018 Aug; 36(4):e12331. PubMed ID: 29656548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relaxin' the Heart: A Novel Therapeutic Modality.
    Raleigh JM; Toldo S; Das A; Abbate A; Salloum FN
    J Cardiovasc Pharmacol Ther; 2016 Jul; 21(4):353-62. PubMed ID: 26589290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydrogen Sulfide Switch Phenomenon Regulating Autophagy in Cardiovascular Diseases.
    Luo W; Gui DD; Yan BJ; Ren Z; Peng LJ; Wei DH; Liu LS; Zhang DW; Jiang ZS
    Cardiovasc Drugs Ther; 2020 Feb; 34(1):113-121. PubMed ID: 32090295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. cGMP Signaling in Cardiovascular Diseases: Linking Genotype and Phenotype.
    Dang TA; Schunkert H; Kessler T
    J Cardiovasc Pharmacol; 2020 Jun; 75(6):516-525. PubMed ID: 32487847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular Effects of Urocortin-2: Pathophysiological Mechanisms and Therapeutic Potential.
    Monteiro-Pinto C; Adão R; Leite-Moreira AF; Brás-Silva C
    Cardiovasc Drugs Ther; 2019 Oct; 33(5):599-613. PubMed ID: 31512017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colchicine for the treatment of cardiovascular diseases: old drug, new targets.
    Andreis A; Imazio M; De Ferrari GM
    J Cardiovasc Med (Hagerstown); 2021 Jan; 22(1):1-8. PubMed ID: 32858634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of imperatorin in the cardiovascular system and cancer.
    Nasser MI; Zhu S; Hu H; Huang H; Guo M; Zhu P
    Biomed Pharmacother; 2019 Dec; 120():109401. PubMed ID: 31622950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypothesis: Metalloproteinase Inhibitors Decrease Risks of Cardiovascular Disease.
    Lizotte-Waniewski M; Brew K; Hennekens CH
    J Cardiovasc Pharmacol Ther; 2016 Jul; 21(4):368-71. PubMed ID: 26703451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kidney-on-a-chip: untapped opportunities.
    Ashammakhi N; Wesseling-Perry K; Hasan A; Elkhammas E; Zhang YS
    Kidney Int; 2018 Dec; 94(6):1073-1086. PubMed ID: 30366681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P2X7 Receptors: An Untapped Target for the Management of Cardiovascular Disease.
    Shokoples BG; Paradis P; Schiffrin EL
    Arterioscler Thromb Vasc Biol; 2021 Jan; 41(1):186-199. PubMed ID: 32998520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activating transcription factor 3 in cardiovascular diseases: a potential therapeutic target.
    Zhou H; Li N; Yuan Y; Jin YG; Guo H; Deng W; Tang QZ
    Basic Res Cardiol; 2018 Aug; 113(5):37. PubMed ID: 30094473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular effects of sphingosine-1-phosphate (S1P).
    Levkau B
    Handb Exp Pharmacol; 2013; (216):147-70. PubMed ID: 23563656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.